Yi Gu
Technik-/Wissenschafts-/F&E-Leiter bei TRANSCENTA HOLDING LIMITED
Profil
Yi Gu is currently a Member at the American Association for Cancer Research since 2009 and a Senior Vice President & Head-Research at Transcenta Holding Ltd.
since 2019.
Previously, Dr. Gu worked as a Director-Translational Sciences at AstraZeneca PLC from 2006 to 2015 and as a Vice President-Research & Development at Ambrx, Inc. from 2016 to 2018.
Dr. Gu holds a doctorate degree from Rochester Christian University, conferred in 1998, and an undergraduate degree from Fudan University, conferred in 1990.
Aktive Positionen von Yi Gu
Unternehmen | Position | Beginn |
---|---|---|
TRANSCENTA HOLDING LIMITED | Technik-/Wissenschafts-/F&E-Leiter | 01.02.2019 |
American Association for Cancer Research
American Association for Cancer Research Miscellaneous Commercial ServicesCommercial Services American Association for Cancer Research prints and publishes scientific journals including clinical cancer research, molecular cancer therapeutics, molecular cancer research, cancer epidemiology, and biomarkers and prevention. The company was founded on May 7, 1907 and is headquartered in Philadelphia, PA. | Corporate Officer/Principal | 01.01.2009 |
Ehemalige bekannte Positionen von Yi Gu
Unternehmen | Position | Ende |
---|---|---|
AMBRX INC | Technik-/Wissenschafts-/F&E-Leiter | 01.12.2018 |
ASTRAZENECA PLC | Corporate Officer/Principal | 01.12.2015 |
Ausbildung von Yi Gu
Fudan University | Undergraduate Degree |
Rochester Christian University | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 2 |
---|---|
TRANSCENTA HOLDING LIMITED | Health Technology |
ASTRAZENECA PLC | Health Technology |
Private Unternehmen | 2 |
---|---|
Ambrx, Inc.
Ambrx, Inc. Pharmaceuticals: MajorHealth Technology Ambrx, Inc. engages in discovering and developing of protein therapeutics. It offers non-native amino acids through expanded genetic code to both generate novel bio-therapeutics. The company was founded by Richard DiMarchi, Peter G. Schultz, and Troy E. Wilson on April 15, 2003 and is headquartered in La Jolla, CA. | Health Technology |
American Association for Cancer Research
American Association for Cancer Research Miscellaneous Commercial ServicesCommercial Services American Association for Cancer Research prints and publishes scientific journals including clinical cancer research, molecular cancer therapeutics, molecular cancer research, cancer epidemiology, and biomarkers and prevention. The company was founded on May 7, 1907 and is headquartered in Philadelphia, PA. | Commercial Services |